Business Context and Reporting Period
This Form 8-K Current Report from Aprea Therapeutics, Inc. (APRE) covers the 2024 Annual Meeting of Stockholders held on June 20, 2024. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Of the 5,430,215 shares entitled to vote, 3,826,179 shares (approximately 70.46%) were represented, constituting a quorum. The following proposals were approved:
- Proposal 1: Election of Class II Directors. Stockholders elected Michael Grissinger, Gabriela Gruia, M.D., and Rifat Pamukcu, M.D. to serve until the 2027 Annual Meeting.
- Michael Grissinger: 3,051,902 votes for; 54,753 withheld.
- Gabriela Gruia, M.D.: 3,088,199 votes for; 18,456 withheld.
- Rifat Pamukcu, M.D.: 3,056,175 votes for; 50,480 withheld.
- Proposal 2: Ratification of Independent Auditor. Stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for fiscal year 2024.
- Votes For: 3,788,888
- Votes Against: 7,750
- Votes Abstaining: 29,541
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. For further details on the proposals, the Company refers investors to the definitive proxy statement on Schedule 14A filed on April 25, 2024.
Investor Verification Checklist
- Verify the tenure of the newly elected Class II directors (Michael Grissinger, Gabriela Gruia, M.D., and Rifat Pamukcu, M.D.) through the 2027 Annual Meeting.
- Confirm the engagement of EisnerAmper LLP as the independent auditor for the 2024 fiscal year.
- Review the Schedule 14A proxy statement filed on April 25, 2024, for detailed background on the director nominees and auditor selection.
- Note that 719,524 broker non-votes were recorded for the director election, indicating shares held by brokers that did not receive voting instructions.